A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM subjects (Brain Tumors)
Study of Vaccine for Cytomegalovirus (CMV) in Patients with Brain Tumors
Sponsor: VBI Vaccines, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5300
U.S. Govt. ID: NCT03382977
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.
Andrew Lassman, MD
Do You Qualify?
Are you between the ages of 18-70? Yes No
Have you been diagnosed with a glioblastoma (type of brain cancer)? Yes No
Has your tumor come back or progressed after an initial treatment? Yes No
Have you recovered from surgery? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator